INTEGRA Biosciences’ VIAFLO 96 electronic multi-channel pipetting system is helping biotechnology company HCS Pharma to improve the reproducibility of high content screening using its patented BIOMIMESYS 3D cell culture technology. Elodie Vandenhaute, Study Director at HCS Pharma, explained: “96-well cell culture plates are not easy to handle, even with multi-channel pipettes. The VIAFLO 96 is really user-friendly and allows us to, for example, seed cells, dispense reagents or perform media exchanges in every well simultaneously. This is both extremely convenient, saving the operator a lot of time, and helps to improve the reproducibility of results by allowing more precise manipulation of cultures. This is particularly important during media exchange, as you need to avoid disturbing the gel. With the VIAFLO 96, you can do this very easily and consistently, without the risk of accidents, making our experiments more reproducible.
“The system is very compact, which means that it easily fits under our existing laminar flow hood, which is a real advantage, as the cell cultures remain within a sterile environment for manipulation, which is very important for cell seeding and changing media. It saves space and is cost-effective compared to a fully automated liquid handling robot – it’s a great intermediate between a handheld pipette and a robot.”
For further information about INTEGRA Biosciences visit www.integra-biosciences.com
Latest from Tom Mulligan
- COMPANY UPDATE: Metrion Biosciences and the potential for ion channel drug discovery
- EVENT PREVIEW: Get ready for DCAT Week in New York this month!
- MEDICINES FOR THE 21st CENTURY conference takes place in Cardiff, UK in May
- Aigenpulse receives ISO 9001:2015 and ISO 27001:2013 certification for AI data technology
- FUJIFILM SonoSite launches redesigned SonoSite Institute
- Moderna exercises exclusive licence option for Avacta Affimer biotherapeutics development
- Sphere Fluidics closes $2 million investment round
- Horizon Discovery and Rutgers University form exclusive partnership to develop novel next-generation gene editing technology
- Optibrium appoints Clare Devlin as financial director
- Dolomite Microfluidics technology enables formulation of liposomal RNA vaccine delivery systems